Wednesday, 2 July 2025
  
Login

Australia's most trusted
source of pharma news

Wednesday, 02 July 2025
News

ST snags lucrative licence

Posted 25 October 2021 AM

Specialised Therapeutics (ST) has struck a deal with Incyte Biosciences, the Swiss-based affiliate of Incyte to launch two new cancer therapies in three jurisdictions, including Australia.

Under the terms of the agreement, ST will be responsible for regulatory, distribution and local marketing related activities for tafasitamab (sold as Monjuvi in the US and Minjuvi in Europe) and Pemazyre in Australia, New Zealand and Singapore.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (10)

Clinical & Medical, R&D (11)

Regulatory, Pharmacovigilance & QA (1)

Devices (1)

Other (9)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.